![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/tiumbio-presents-promising-clinical-data-from-phase-1-of-its-hemophilia-treatment-candidate-tu7710-at-isth-2024-302180104.html
https://www.prnewswire.com/news-releases/tiumbio-presents-phase-1b-interim-results-for-tu2218-in-combination-with-pembrolizumab-at-asco-2024-annual-meeting-302160236.html
https://www.prnewswire.com/news-releases/tiumbio-announces-positive-topline-data-from-phase-2a-trial-of-merigolix-in-patients-with-moderate-to-severe-endometriosis-associated-pain-302139490.html
https://www.prnewswire.com/news-releases/tiumbio-submits-cta-for-phase-1b-clinical-trial-of-tu7710-a-long-acting-recombinant-activated-factor-vii-in-hemophilia-a-or-b-patients-302099347.html
https://www.prnewswire.com/news-releases/tiumbio-secures-krw-38-5-billion-in-anticipation-of-upcoming-clinical-data-302023671.html
https://www.prnewswire.com/news-releases/tiumbio-and-hansoh-pharma-announce-clinical-trial-approval-of-hs-10518tu2670-from-nmpa-in-china-301869971.html